BRPI0804623A2 - uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos - Google Patents
uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivosInfo
- Publication number
- BRPI0804623A2 BRPI0804623A2 BRPI0804623-9A BRPI0804623A BRPI0804623A2 BR PI0804623 A2 BRPI0804623 A2 BR PI0804623A2 BR PI0804623 A BRPI0804623 A BR PI0804623A BR PI0804623 A2 BRPI0804623 A2 BR PI0804623A2
- Authority
- BR
- Brazil
- Prior art keywords
- drug
- preparation
- treatment
- patients suffering
- human albumin
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 5
- 102000008100 Human Serum Albumin Human genes 0.000 title abstract 4
- 108091006905 Human Serum Albumin Proteins 0.000 title abstract 4
- 208000010877 cognitive disease Diseases 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 4
- 229940079593 drug Drugs 0.000 title abstract 4
- 208000028698 Cognitive impairment Diseases 0.000 title abstract 2
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
USO DE ALBUMINA HUMANA TERAPêUTICA PARA A PREPARAçãO DE UM FáRMACO PARA O TRATAMENTO DE PACIENTES SOFRENDO DE DISTúRBIOS COGNITIVOS. A presente invenção refere-se ao uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos. A invenção é baseada no uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos, em que o modelo de administração do fármaco inclui a administração ao paciente por um mínimo de três vezes sucessivas, de uma quantidade terapeuticamente eficiente de albumina terapêutica humana por meio de troca de plasma e/ou de perfusão intravenosa, independente do conteúdo de A<225> no sangue do paciente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200702831A ES2332846B1 (es) | 2007-10-26 | 2007-10-26 | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos. |
| ES200702831 | 2007-10-26 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0804623A2 true BRPI0804623A2 (pt) | 2009-06-30 |
| BRPI0804623B1 BRPI0804623B1 (pt) | 2020-02-11 |
| BRPI0804623B8 BRPI0804623B8 (pt) | 2021-05-25 |
Family
ID=40583637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0804623A BRPI0804623B8 (pt) | 2007-10-26 | 2008-10-23 | uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7851446B2 (pt) |
| EP (1) | EP2111868B1 (pt) |
| JP (1) | JP5437619B2 (pt) |
| CN (1) | CN101417123B (pt) |
| AR (1) | AR068901A1 (pt) |
| AU (1) | AU2008233025B8 (pt) |
| BR (1) | BRPI0804623B8 (pt) |
| CA (1) | CA2641830C (pt) |
| CL (1) | CL2008003133A1 (pt) |
| ES (2) | ES2332846B1 (pt) |
| MX (1) | MX2008013635A (pt) |
| NZ (1) | NZ572131A (pt) |
| PL (1) | PL2111868T3 (pt) |
| PT (1) | PT2111868E (pt) |
| RU (1) | RU2414925C2 (pt) |
| UY (1) | UY31418A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10112000B2 (en) | 2010-07-08 | 2018-10-30 | Asahi Kasei Medical Co., Ltd. | Method for reducing amyloid beta concentration in blood |
| SG11201901273TA (en) * | 2016-08-18 | 2019-03-28 | Alkahest Inc | Blood plasma fractions as a treatment for aging-associated cognitive disorders |
| EA039316B1 (ru) * | 2016-10-24 | 2022-01-12 | Алкахест, Инк. | Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением |
| CN117899111A (zh) * | 2017-04-26 | 2024-04-19 | 万能溶剂有限公司 | 用血浆和血浆制品治疗认知障碍和运动障碍的给药方案 |
| US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| KR20210024196A (ko) * | 2018-07-20 | 2021-03-04 | 알카헤스트 인코포레이티드 | 혈장 및 혈장 산물로 인지 및 운동 장애를 치료하기 위한 투여 요법 |
| EP3643319A1 (en) * | 2018-10-25 | 2020-04-29 | Grifols Worldwide Operations Limited | Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages |
| UA128648C2 (uk) | 2018-10-26 | 2024-09-18 | Алкахест, Інк. | Застосування плазми крові та фракцій плазми для пом'якшення болю, поліпшення загоювання ран та післяопераційного відновлення |
| JP2023547479A (ja) | 2020-10-30 | 2023-11-10 | シェンチェン、プロトゲン、リミテッド | 疾患の治療におけるヒト血清アルブミンの使用 |
| BR112023020972A2 (pt) * | 2021-04-30 | 2023-12-12 | Grifols Worldwide Operations Ltd | Uso de troca de plasma terapêutico e baixo volume de troca de plasma para o tratamento de uma diminuição cognitiva |
| WO2025230830A1 (en) | 2024-04-29 | 2025-11-06 | Alkahest, Inc. | Compositions of blood plasma fractions and their use in treatment of spinal muscular atrophy (sma) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3612137A1 (de) | 1986-04-10 | 1987-10-15 | Biotest Pharma Gmbh | Steriles plasmaaustauschmittel |
| US5112298A (en) | 1990-06-25 | 1992-05-12 | Baxter International Inc. | Apheresis method and device |
| US5178603A (en) | 1990-07-24 | 1993-01-12 | Baxter International, Inc. | Blood extraction and reinfusion flow control system and method |
| US6627151B1 (en) * | 1997-06-13 | 2003-09-30 | Helmut Borberg | Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion |
| WO2001090758A2 (en) | 2000-05-23 | 2001-11-29 | The University Of Southern California | Diagnosis of alzheimer's disease ldl receptor protein-1 |
| WO2002078670A1 (en) * | 2001-03-02 | 2002-10-10 | Neuron Therapeutics, Inc. | Neuroprotectants formulations and methods |
| WO2003051374A2 (en) | 2001-12-17 | 2003-06-26 | New York State Office Of Mental Health | SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES |
| EP1558585B1 (en) | 2002-10-04 | 2013-09-25 | Prana Biotechnology Limited | Neurologically-active compounds |
| US20070010435A1 (en) | 2002-12-19 | 2007-01-11 | New York University | Method for treating amyloid disease |
| RS50891B (sr) | 2003-02-13 | 2010-08-31 | Octapharma Ag. | Postupak za pripremanje rastvora albumina |
| CA2532207A1 (en) | 2003-07-11 | 2005-07-21 | Myriad Genetics, Inc. | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease |
| AT413336B (de) * | 2003-09-12 | 2006-02-15 | Mattner Frank Dr | Apherese-vorrichtung |
| US20050182044A1 (en) | 2004-02-17 | 2005-08-18 | Bruinsma Gosse B. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate |
| AT500483B1 (de) | 2004-07-13 | 2006-01-15 | Mattner Frank Dr | Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung |
| RU2261702C1 (ru) * | 2004-09-23 | 2005-10-10 | Смирнов Алексей Владимирович | Способ лечения гипергомоцистеинемии у больных с хронической почечной недостаточностью, получающих лечение гемодиализом или гемофильтрацией |
| RU2281090C2 (ru) * | 2004-09-23 | 2006-08-10 | Алексей Владимирович Смирнов | Способ лечения больных хронической почечной недостаточностью |
| US7436304B1 (en) | 2005-07-19 | 2008-10-14 | Visible Assets, Inc | Evidence tracking |
-
2007
- 2007-10-26 ES ES200702831A patent/ES2332846B1/es not_active Expired - Fee Related
-
2008
- 2008-10-17 RU RU2008141076/15A patent/RU2414925C2/ru active
- 2008-10-17 NZ NZ572131A patent/NZ572131A/en unknown
- 2008-10-17 AR ARP080104523A patent/AR068901A1/es unknown
- 2008-10-22 ES ES08380301T patent/ES2428698T3/es active Active
- 2008-10-22 PT PT83803015T patent/PT2111868E/pt unknown
- 2008-10-22 PL PL08380301T patent/PL2111868T3/pl unknown
- 2008-10-22 EP EP08380301.5A patent/EP2111868B1/en active Active
- 2008-10-23 CL CL2008003133A patent/CL2008003133A1/es unknown
- 2008-10-23 MX MX2008013635A patent/MX2008013635A/es active IP Right Grant
- 2008-10-23 BR BRPI0804623A patent/BRPI0804623B8/pt active IP Right Grant
- 2008-10-23 UY UY31418A patent/UY31418A1/es not_active Application Discontinuation
- 2008-10-23 CN CN2008101705786A patent/CN101417123B/zh active Active
- 2008-10-24 JP JP2008274076A patent/JP5437619B2/ja active Active
- 2008-10-24 CA CA2641830A patent/CA2641830C/en active Active
- 2008-10-24 US US12/257,814 patent/US7851446B2/en active Active
- 2008-10-24 AU AU2008233025A patent/AU2008233025B8/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0804623B8 (pt) | 2021-05-25 |
| MX2008013635A (es) | 2009-05-11 |
| PL2111868T3 (pl) | 2014-01-31 |
| ES2332846A1 (es) | 2010-02-12 |
| NZ572131A (en) | 2010-06-25 |
| CA2641830A1 (en) | 2009-04-26 |
| JP5437619B2 (ja) | 2014-03-12 |
| AU2008233025B8 (en) | 2013-07-25 |
| EP2111868A1 (en) | 2009-10-28 |
| US20090111740A1 (en) | 2009-04-30 |
| CA2641830C (en) | 2013-07-16 |
| RU2008141076A (ru) | 2010-04-27 |
| CN101417123A (zh) | 2009-04-29 |
| PT2111868E (pt) | 2013-10-17 |
| US7851446B2 (en) | 2010-12-14 |
| RU2414925C2 (ru) | 2011-03-27 |
| EP2111868B1 (en) | 2013-08-21 |
| AU2008233025B2 (en) | 2013-06-27 |
| ES2428698T3 (es) | 2013-11-08 |
| AR068901A1 (es) | 2009-12-16 |
| ES2332846B1 (es) | 2010-07-08 |
| UY31418A1 (es) | 2009-05-29 |
| CL2008003133A1 (es) | 2009-08-07 |
| CN101417123B (zh) | 2012-06-27 |
| AU2008233025A1 (en) | 2009-05-14 |
| JP2009108059A (ja) | 2009-05-21 |
| BRPI0804623B1 (pt) | 2020-02-11 |
| HK1126689A1 (en) | 2009-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0804623B8 (pt) | uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos | |
| American Society of Anesthesiologists Task Force on Chronic Pain Management | Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine | |
| JP2022009125A5 (pt) | ||
| NZ597378A (en) | Treatment of multiple sclerosis with laquinimod | |
| EP2216024A3 (en) | Use of Ranolazine for the treatment of cardiovascular diseases | |
| BRPI0820800A2 (pt) | Dispositivo médico implantável para liberação controlada de droga, e, métodos para administração de uma droga na bexiga de um paciente e para tratar a bexiga em um paciente | |
| WO2007109006A3 (en) | Infusion device capable of providing multiple liquid medicaments | |
| WO2008022189A3 (en) | Administration of high potency platinum compound formulations by inhalation | |
| HK1202776A1 (en) | Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy | |
| EP3247352A1 (en) | Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function | |
| Chen et al. | Efficacy and safety of dexmedetomidine versus propofol for the sedation of tube-retention after oral maxillofacial surgery | |
| JP2010518164A5 (pt) | ||
| CY1115269T1 (el) | Χρηση ανταγωνιστων οπιοειδων για την παρασκευη ενος φαρμακου στη θεραπευτικη αγωγη εκφυλιστικων ασθενειων του αμφιβληστροειδους | |
| RU2013112890A (ru) | Терапевтическое применение 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина | |
| BR112014004339A2 (pt) | suspensão oral | |
| RU2006101061A (ru) | Азенапин для лечения шизофрении у пациентов с избыточной массой тела или предрасположенностью к избыточной массе тела | |
| Usichenko et al. | Auricular acupuncture | |
| Cangemi Jr | Administration of general anesthesia for outpatient orthognathic surgical procedures | |
| WO2008079818A3 (en) | Intravenous administration of water soluble analgesic formulations | |
| Winter et al. | 0561 Solriamfetol Real World Experience Study: Safety, Efficacy, and Follow-Up for Patients with Obstructive Sleep Apnea in Germany | |
| NZ599227A (en) | Therapeutic agent for chronic pain | |
| JP2010519274A5 (pt) | ||
| Wong et al. | Sedation and Analgesia for HIFU Ablation | |
| Almomani | The effect of ketamine on blood pressure, heart rate, respiratory rate and intraocular pressure in patients undergoing ocular procedures | |
| CN2912665Y (zh) | 新型输液瓶 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B03A | Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: GRIFOLS, S.A. (ES) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/02/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |